ArticleWorld journal of gastroenterology2020
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.
Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity.International journal of molecular sciences · 2021Trial
- Outcomes of Acute Pancreatitis in Lean Versus Non-lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: A Nationwide Analysis.Digestive diseases and sciences · 2025Article
- Association between TyG index and MASLD in lean young adults: a retrospective study.BMC endocrine disorders · 2025Article
- Clinical Outcomes in Acute Decompensated Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis: The Role of BMI in Mortality, Readmission, and Hospital Stay.Journal of general internal medicine · 2025Article
- Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.Clinical and experimental medicine · 2025Article
- Endonuclease G promotes hepatic mitochondrial respiration by selectively increasing mitochondrial tRNAProceedings of the National Academy of Sciences of the United States of America · 2025Article
- The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different?Frontiers in endocrinology · 2025Review
- Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.Journal of cachexia, sarcopenia and muscle · 2024Article
- Metabolic dysfunction associated fatty liver disease in healthy weight individuals.Hepatology international · 2024Review
- Review
- Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison.International journal of molecular sciences · 2024Review
- Article
- Clinical correlates of CT imaging-derived phenotypes among lean and overweight patients with hepatic steatosis.Scientific reports · 2024Article
- Diagnostic Utility of Triglyceride-Glucose Index in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study on Lean Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Observational
- Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2023Review
- Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment.Journal of clinical and translational hepatology · 2023Review
- Non-alcoholic fatty liver disease: Definition and subtypes.Clinical and molecular hepatology · 2023Review
- Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease.Frontiers in endocrinology · 2023Article
- Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) accounts for most cases of chronic liver disease worldwide, with an estimated global prevalence of approximately 25% and ranges from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. NAFLD is strongly connected to metabolic syndrome, and for many years, fatty liver was considered to be an exclusive feature of obese patients. However, recent studies have highlighted the presence of NAFLD in non-obese subjects, with or without increased visceral fat or even in lean subjects without increased waist circumference. "Lean NAFLD" is a relatively new concept and there is significant scientific interest in understanding the differences in pathophysiology, prognosis and management compared with NAFLD in overweight/obese patients. In the present editorial, we discuss the clinical and metabolic profiles and outcomes of lean NAFLD compared with both obese NAFLD and lean healthy individuals from Asian and Western countries. Moreover, we shed light to the challenging topic of management of NAFLD in lean subjects since there are no specific guidelines for this population. Finally, we discuss open questions and issues to be addressed in the future in order to categorize NAFLD patients into lean and non-lean cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.